Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Knightscope
Sponsored
content by Knightscope
MA
MarketJar
Community Contributor
The Next Phase of Defense AI: A Robotic Response to America’s Security Gaps
Autonomous systems are no longer just a futuristic vision — they’re fast becoming an essential layer of national security. As AI reshapes everything from finance to warfare, physical security remains one of the most under-addressed frontiers.
View narrative
US$12.00
FV
51.2% undervalued
intrinsic discount
22.00%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
1
users have commented on this narrative
23
users have followed this narrative
New
narrative
Figma
TI
TickerTickle
Community Contributor
Figma (FIG): The S&P 500’s Design Standard Turning Into an All-in-One Platform
Watching Figma Grow Up I’ve been using Figma almost every single day for the past five years. As a product designer, it’s been my main tool for designing interfaces, testing and prototyping ideas, and also for working together with teams in different countries and time zones.
View narrative
US$65.70
FV
6.7% overvalued
intrinsic discount
30.00%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
Updated
narrative
Sleep Cycle
MA
Mandelman
Community Contributor
Sleep Cycle's Revenue Set to Rise 10% with Strong Revenue Model
Update Q1 2025 (updated 250510) The latest user‐growth data suggest headwinds for top-line revenue, but management’s active repricing initiatives should help offset this. By combining modest user gains with targeted price increases, the company can still drive overall revenue growth.
View narrative
SEK 38.04
FV
24.6% undervalued
intrinsic discount
3.15%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
1
users have commented on this narrative
24
users have followed this narrative
Updated
narrative
JB Hi-Fi
RO
Robbo
Community Contributor
Has JB Hi-Fi Lost Its Point of Difference?
I may be showing my age here, but I feel that a decade or so ago, shopping at JB Hi-Fi was a different experience. There seemed to be a deliberate policy of employing sales staff from alternative subcultures, which gave the stores a unique, edgy vibe.
View narrative
AU$76.00
FV
51.4% overvalued
intrinsic discount
-0.45%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
1
users have commented on this narrative
5
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
GoHealth
AN
AnalystLowTarget
Consensus Narrative from 5 Analysts
Rising Medicare Uncertainties Will Press Margins But Stability Will Emerge
Key Takeaways Exposure to regulatory shifts and the rise of digital insurance platforms may threaten GoHealth's revenue stability and erode its core business. Persistent high customer acquisition costs, margin pressures, and volatile carrier dynamics could undermine sustainable earnings improvement.
View narrative
US$16.00
FV
66.2% undervalued
intrinsic discount
5.33%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
11 days ago
author updated this narrative
Euroapi
AN
AnalystLowTarget
Consensus Narrative from 5 Analysts
Rising Regulatory And Geopolitical Risks Will Undermine API Profits
Key Takeaways Intensifying regulatory pressures and global deglobalization trends threaten profitability and export-driven growth, especially amid shifting mandates for local drug production. Heavy reliance on a few key clients and shrinking demand for traditional APIs expose the company to heightened revenue volatility and margin pressure.
View narrative
€2.50
FV
21.2% overvalued
intrinsic discount
-2.06%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
11 days ago
author updated this narrative
Blade Air Mobility
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Delays Will Slow Organ Transport Yet Offer Future Value
Key Takeaways Heavy dependence on organ transport growth and uncertain regulatory or technological adoption pose risks to revenue stability and margin expansion. Delays in eVTOL adoption or high fixed costs could constrain cost savings, while integration and environmental challenges may hamper long-term profit growth.
View narrative
US$5.00
FV
8.6% undervalued
intrinsic discount
7.65%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
11 days ago
author updated this narrative
Yatsen Holding
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
China's Aging Population And Rising Costs Will Constrain Profitability
Key Takeaways Shifting demographics, economic headwinds, and intensifying competition threaten revenue stability and long-term growth for Yatsen's core brands. Increasing regulatory pressures and changing consumer trends drive up compliance, marketing, and R&D costs, squeezing margins and profitability.
View narrative
US$3.44
FV
182.2% overvalued
intrinsic discount
21.39%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
11 days ago
author updated this narrative
Health Catalyst
AN
AnalystLowTarget
Consensus Narrative from 9 Analysts
Medicaid Cuts Will Constrict Deals But Spur Efficiency
Key Takeaways Ongoing client budget cuts and cautious spending habits are limiting revenue growth and reducing average revenue per customer, stalling expansion from existing clients. Strategic focus on efficiency and shifting toward higher-margin technology may improve profitability, but could further constrain top-line growth and heighten volatility.
View narrative
US$3.00
FV
16.7% overvalued
intrinsic discount
0.091%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
11 days ago
author updated this narrative
8x8
AN
AnalystLowTarget
Consensus Narrative from 8 Analysts
Microsoft And Cisco Will Intensify Pricing And Compliance Pressures
Key Takeaways Intensifying competition and lack of product differentiation threaten market share, pricing power, and customer retention, keeping growth below peers. Rising compliance and marketing costs are squeezing margins and delaying the path to sustained profitability.
View narrative
US$1.50
FV
24.0% overvalued
intrinsic discount
-0.12%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
11 days ago
author updated this narrative
Personalis
AN
AnalystLowTarget
Consensus Narrative from 8 Analysts
Delays And Scrutiny Will Limit Revenue But Enable Future Adaptation
Key Takeaways Growing demand for precision medicine drives long-term opportunity, but delayed pharma projects and reimbursement challenges threaten near-term revenue stability and margin expansion. Intensifying competition, regulatory pressures, and persistent operating losses risk constraining profitability and may force cost cuts or future shareholder dilution.
View narrative
US$5.00
FV
2.4% undervalued
intrinsic discount
17.05%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
11 days ago
author updated this narrative
BARK
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Rising Costs And Rivalry Will Limit Gains As Niches Emerge
Key Takeaways Inflation and cost pressures threaten discretionary spending and subscription growth, limiting BARK's ability to fully capture demand from trends in pet wellness and customization. Difficulty scaling new product categories, high competition, and persistent subscriber churn challenge revenue diversification, margin expansion, and long-term profitability.
View narrative
US$2.00
FV
56.5% undervalued
intrinsic discount
0.75%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
11 days ago
author updated this narrative
Valens Semiconductor
AN
AnalystLowTarget
Consensus Narrative from 4 Analysts
Tariff Uncertainty Will Limit Automotive Revenues But Benefit Margins
Key Takeaways Heavy reliance on automotive sector exposes Valens to risks from industry volatility, shifting design standards, and customer concentration. Rising competition and regulatory costs threaten profitability, with potential pricing pressure and increased expenses from sustainable manufacturing requirements.
View narrative
US$3.00
FV
32.0% undervalued
intrinsic discount
17.18%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
11 days ago
author updated this narrative
Value any company in seconds
Popular companies